Skip to main content
OpenTrials
Completed

NCT Number: NCT05031832

Chemsex Engagement and HIV Biomedical Prevention in MSM

HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Recreational Drug Use Behavior Homosexuality Sexual Behavior Sexuality

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

The Chinese University of Hong Kong

Hong Kong, 0000

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • aged 18 or above
  • male
  • have had sex with men since 2019
  • could be communicated in English or Chinese

Exclusion criteria

  • failed to provide consent

Treatment and study plan

HIV test

Diagnostic Test

HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status

Primary outcomes

  1. pre-exposure prophylaxis coverage

    Time frame: 6 months

    proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire

  2. Good antiretroviral therapy adherence

    Time frame: 2 years

    proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire

  3. Drug use pattern

    Time frame: 6 months

    types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Official study title

The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Sep 2, 2021
Registry last updated
Jan 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.